A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CART-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

被引：25
|
作者：
Shah, Nirav N. [1 ]
Zhu, Fenlu [2 ]
Taylor, Carolyn [2 ]
Schneider, Dina [3 ]
Krueger, Winfried [3 ]
Worden, Andrew [3 ]
Yim, Sharon [2 ]
Fenske, Timothy S. [1 ]
Hamadani, Mehdi [1 ]
Johnson, Bryon [4 ]
Dropulic, Boro [5 ]
Orentas, Rimas [3 ]
Hari, Parameswaran [6 ]
机构：
[1] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Lentigen Technol Inc, Gaithersburg, MD USA
[4] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[5] Lentigen, Gaithersburg, MD USA
[6] Med Coll Wisconsin, Dept Med, Menomonee Falls, WI USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110194
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4193
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
    Nirav N. Shah
    Bryon D. Johnson
    Dina Schneider
    Fenlu Zhu
    Aniko Szabo
    Carolyn A. Keever-Taylor
    Winfried Krueger
    Andrew A. Worden
    Michael J. Kadan
    Sharon Yim
    Ashley Cunningham
    Mehdi Hamadani
    Timothy S. Fenske
    Boro Dropulić
    Rimas Orentas
    Parameswaran Hari
    Nature Medicine, 2020, 26 : 1569 - 1575
  • [32] Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma
    Shah, Nirav N.
    Furqan, Fateeha
    Szabo, Aniko
    Neumann, Jessica
    Hari, Parameswaran
    Schneider, Dina
    Johnson, Bryon
    Hamadani, Mehdi
    Fenske, Timothy S.
    BLOOD, 2022, 140 : 9318 - 9319
  • [33] COMBINATION OF IBRUTINIB AND ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF RELAPSING/ REFRACTORY MANTLE CELL LYMPHOMA (MCL)
    Ruella, M.
    Kenderian, S.
    Fraietta, J.
    Shestova, O.
    Qayyum, S.
    Zhang, Q.
    Liu, X.
    Maus, M.
    Lacey, S.
    Mato, A.
    Schuster, S.
    June, C.
    Wasik, M.
    Gill, S.
    HAEMATOLOGICA, 2015, 100 : 287 - 288
  • [34] Sequential treatment with anti-CD19 and CD22 chimeric antigen receptor T cells in children with relapsed or refractory B acute lymphoblastic leukemia
    Chanut, Mathilde
    HEMATOLOGIE, 2023, 29 (06): : 332 - 334
  • [35] Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Borchmann, Peter
    Juhling, Anja
    Godel, Philipp
    Balke-Want, Hyatt
    Schmid, Christoph
    Ayuk, Francis A.
    Holtkamp, Silke
    Preussner, Liane
    Zadoyan, Gregor
    Hanssens, Linda
    Kaiser, Andrew
    Jurk, Marion
    Burger, Iris
    Schneider, Dina
    Dropulic, Boro
    Overstijns, Toon
    Scheid, Christof
    Holtick, Udo
    Miltenyi, Stefan
    Hallek, Michael
    BLOOD, 2020, 136
  • [36] Phase I trial of MB-CART2019.1, a novel CD20 and CD19 targeting tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma
    Borchmann, P.
    Juehling, A.
    Goedel, P.
    Balke-Want, H.
    Schmid, C.
    Ayuk, F.
    Holtkamp, S.
    Preussner, L.
    Zadoyan, G.
    Hanssens, L.
    Kaiser, A.
    Jurk, M.
    Buerger, I
    Schneider, D.
    Dropulic, B.
    Overstijns, T.
    Holtick, U.
    Scheid, C.
    Miltenyi, S.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 56 - 56
  • [37] Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma
    Hairuo Wen
    Xiaoyan Lou
    Zhe Qu
    Chao Qin
    Hua Jiang
    Ying Yang
    Liqing Kang
    Xingchao Geng
    Lei Yu
    Ying Huang
    Discover Oncology, 13
  • [38] Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma
    Wen, Hairuo
    Lou, Xiaoyan
    Qu, Zhe
    Qin, Chao
    Jiang, Hua
    Yang, Ying
    Kang, Liqing
    Geng, Xingchao
    Yu, Lei
    Huang, Ying
    DISCOVER ONCOLOGY, 2022, 13 (01)
  • [39] Therapeutic combination by T cells with anti-CD19 and anti-chimeric antigen receptors for maturation of relapsed or refractory multiple myeloma B cells
    Stocker, Nicolas
    HEMATOLOGIE, 2019, 25 (06): : 285 - 285
  • [40] Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma
    Ye, Shiguang
    Zhou, Lili
    Li, Shaoguang
    Li, Ping
    Liang, Aibin
    BLOOD, 2019, 134
12345